Florence Broussais

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 428 citations

Medicine, Pharmacokinetics, Pharmacology +13

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 383 citations · Full text

Medicine, Hematology, Oncology +15

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy et al. · Blood · 2022 · 148 citations · Full text

Medicine, Immunology, Oncology +16

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

Gaëlle Fossard, Florence Broussais, Inês Coelho et al. · Annals of Oncology · 2017 · 140 citations · Full text

Medicine, Hematology, Oncology +11

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier et al. · Oncotarget · 2018 · 136 citations · Full text

Pharmacy, Oncology, Pharmacology +17